Normal Glypican-3 Serum Levels Do Not Eliminate the Risk of Hepatocellular Carcinoma

被引:0
|
作者
Lembas, Agnieszka [1 ,2 ]
Mikula, Tomasz [1 ,2 ]
Suchacz, Magdalena [1 ,2 ]
Kozlowska, Joanna [1 ,2 ]
Barczak, Szymon [3 ]
Badura, Barbara [3 ]
Wiercinska-Drapalo, Alicja [1 ,2 ]
机构
[1] Med Univ Warsaw, Dept Infect & Trop Dis & Hepatol, Warsaw, Poland
[2] Warsaws Hosp Infect Dis, Warsaw, Poland
[3] Med Univ Warsaw, Dept Infect & Trop Dis & Hepatol, Students Sci Soc, Warsaw, Poland
关键词
Hepatocellular Carcinoma; Glypican-3; Biomarkers; ALPHA-FETOPROTEIN; DIAGNOSTIC-VALUE; LIVER; BIOMARKERS; EXPRESSION; MARKER; HCC;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction. Hepatocellular carcinoma (HCC) is a malignancy that primarily affects patients with liver cirrhosis. Early diagnosis is crucial for improving patient outcomes. The study aimed to investigate the potential role of glypican-3 (GPC3) serum levels, both alone and in combination with alpha-fetoprotein (AFP) and gamma-glutamyl transpeptidase (GGT) serum levels, as diagnostic biomarkers for HCC. Methods. The study included 53 patients with liver cirrhosis and confirmed HCC, who were admitted to the Department of Infectious Diseases, Tropical Diseases and Hepatology at the Medical University of Warsaw, Warsaw, Poland, underwent physical examination and laboratory testing and were compared with 29 healthy volunteers. GPC3, along with demographic data, Child-Pugh and Model for End-Stage Liver Disease (MELD) scores, AFP, and GGT levels, was analyzed in relation to HCC diagnosis. The sensitivity and specificity of GPC3 alone and in combination with AFP and GGT were evaluated for diagnosing HCC. Results. The difference in serum GPC3 levels between patients with HCC and the control group was statistically insignificant (p=0.765). However, a significant correlation was found between GPC3 and AFP serum levels in patients with HCC (p=0.009). Additionally, a correlation was observed between higher GPC3 serum levels within the normal range and the occurrence of HCC. The sensitivity for GPC3 levels greater than 75 ng/ml for detecting HCC was 93.1%, while the specificity was 49.1%. The utility of GPC3, when combined with AFP and GGT, was inconsistent across different thresholds in detecting HCC. Conclusions. The serum levels of GPC3 do not provide satisfactory effectiveness in detecting HCC, and the disease can occur in patients with GPC3 serum concentrations within the normal range. In patients with liver cirrhosis, serum GPC3 levels above 75.00 ng/ml may suggest an increased risk of HCC development. Additionally, the combination of AFP, GPC3, and GGT demonstrates some utility in detecting HCC; however, it shows no superiority over GPC3 alone.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Glypican-3 as a serum marker for hepatocellular carcinoma
    Capurro, M
    Filmus, J
    CANCER RESEARCH, 2005, 65 (01) : 372 - 372
  • [2] Glypican-3: A novel serum and histochemical marker for hepatocellular carcinoma
    Capurro, M
    Wanless, IR
    Sherman, M
    Deboer, G
    Shi, W
    Miyoshi, E
    Filmus, J
    GASTROENTEROLOGY, 2003, 125 (01) : 89 - 97
  • [4] Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma
    Liu, Hui
    Li, Peng
    Zhai, Yun
    Qu, Chun-Feng
    Zhang, Li-Jie
    Tan, Yu-Fen
    Li, Ning
    Ding, Hui-Guo
    WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (35) : 4410 - 4415
  • [5] Upregulation of Glypican-3 in Human Hepatocellular Carcinoma
    Beppu, Tetsuya
    Suzuki, Masahiro
    Sugimoto, Kazushi
    Tanaka, Junnichiro
    Tameda, Masahiko
    Inagaki, Yuji
    Kusagawa, Satoko
    Nojiri, Keiichiro
    Yamamoto, Norihiko
    Uchida, Kazuhiko
    Takase, Koujiro
    Shiraki, Katsuya
    GASTROENTEROLOGY, 2012, 142 (05) : S972 - S972
  • [6] Glypican-3 is overexpressed in human hepatocellular carcinoma
    Sung, YK
    Hwang, SY
    Park, MK
    Farooq, M
    Han, IS
    Bae, HI
    Kim, JC
    Kim, M
    CANCER SCIENCE, 2003, 94 (03): : 259 - 262
  • [7] Epigenetic regulation of glypican-3 in hepatocellular carcinoma
    Trinh, Thu L.
    Puszyk, William
    Liu, Chen
    CANCER RESEARCH, 2014, 74 (19)
  • [8] Evaluation of glypican-3 in patients with hepatocellular carcinoma
    Batbaatar, Batchimeg
    Gurbadam, Unenbat
    Tuvshinsaikhan, Odonchimeg
    Narmandakh, Nyam-Erdene
    Khatanbaatar, Gerelee
    Radnaabazar, Munkhbat
    Erdene-Ochir, Dulguun
    Boldbaatar, Minjuur
    Byambaragchaa, Munkhdelger
    Amankyeldi, Yerbolat
    Chogsom, Munkhzaya
    Ganbileg, Nyamsuren
    Batdelger, Amgalantuul
    Demchig, Tserendorj
    Nyam-Osor, Lkham
    Bayartugs, Batsaikhan
    Batmunkh, Enkhtsatsral
    Munkhjargal, Batkhishig
    Lonjid, Tulgaa
    Khasbagana, Batbayar
    Batmunkh, Munkhbat
    Jav, Sarantuya
    Semchin, Munkhbayar
    MOLECULAR AND CLINICAL ONCOLOGY, 2025, 22 (01)
  • [9] Glypican-3 as a specific biomarker for hepatocellular carcinoma
    Yao, Min
    Pan, Liu-Hong
    Yao, Deng-Fu
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2015, 14 (02) : 122 - 123
  • [10] Glypican-3 as a specific biomarker for hepatocellular carcinoma
    Min Yao
    Liu-Hong Pan
    Deng-Fu Yao
    Hepatobiliary & Pancreatic Diseases International, 2015, 14 (02) : 122 - 123